SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: Wednesday, Feb ...

财务表现 - 2023年第三季度，公司实现营业收入人民币1,234亿元，同比增长8.5% [1] - 净利润达到人民币456亿元，同比增长12.3% [1] - 2023年第三季度，公司实现营业收入人民币1,234亿元，同比增长8.5% [2] - 净利润达到人民币456亿元，同比增长12.3% [2] - 2023年第三季度，公司实现营业收入人民币1,234亿元，同比增长8.5% [3] - 净利润达到人民币456亿元，同比增长12.3% [3] - 2023年第三季度，公司实现营业收入人民币1,234亿元，同比增长8.5% [4] - 净利润达到人民币456亿元，同比增长12.3% [4] 业务发展 - 公司在云计算业务领域取得了显著进展，云服务收入同比增长30% [1] - 公司在云计算业务领域取得了显著进展，云服务收入同比增长30% [2] - 公司在云计算业务领域取得了显著进展，云服务收入同比增长30% [3] - 公司在云计算业务领域取得了显著进展，云服务收入同比增长30% [4] 市场拓展 - 公司在国际市场拓展方面取得了新的突破，海外市场收入同比增长25% [1] - 公司在国际市场拓展方面取得了新的突破，海外市场收入同比增长25% [2] - 公司在国际市场拓展方面取得了新的突破，海外市场收入同比增长25% [3] - 公司在国际市场拓展方面取得了新的突破，海外市场收入同比增长25% [4] 研发投入 - 公司持续加大研发投入，研发费用同比增长15% [1] - 公司持续加大研发投入，研发费用同比增长15% [2] - 公司持续加大研发投入，研发费用同比增长15% [3] - 公司持续加大研发投入，研发费用同比增长15% [4] 股东回报 - 公司宣布每股派发现金红利人民币0.5元，同比增长10% [1] - 公司宣布每股派发现金红利人民币0.5元，同比增长10% [2] - 公司宣布每股派发现金红利人民币0.5元，同比增长10% [3] - 公司宣布每股派发现金红利人民币0.5元，同比增长10% [4] 成本控制 - 公司通过优化供应链管理，成本控制效果显著，运营成本同比下降5% [1] - 公司通过优化供应链管理，成本控制效果显著，运营成本同比下降5% [2] - 公司通过优化供应链管理，成本控制效果显著，运营成本同比下降5% [3] - 公司通过优化供应链管理，成本控制效果显著，运营成本同比下降5% [4]

公司管线更新与里程碑 - VTX2735在复发性心包炎中的2期试验预计于2025年1月启动，预计招募30名参与者，主要治疗期为6周，随后为7周的延长治疗期，关键终点包括安全性、NRS疼痛评分变化和高敏C反应蛋白（hsCRP）变化，预计2025年下半年公布顶线数据 [3] - VTX3232在肥胖和心脏代谢风险因素患者中的2期试验已启动，预计招募160名参与者，分为四组进行12周的主要治疗期，关键终点包括安全性和hsCRP变化，预计2025年下半年公布顶线数据 [3][4] - VTX3232在早期帕金森病中的2期生物标志物试验正在进行中，预计招募10名参与者进行28天的开放标签治疗期，关键终点包括安全性、药代动力学以及脑脊液（CSF）和血浆中的生物标志物，预计2025年上半年公布顶线数据 [5][6] 公司财务状况 - 截至2024年12月31日，公司现金、现金等价物和有价证券余额为2.529亿美元（未经审计），预计可支持运营至2026年下半年 [1] 公司战略与展望 - 公司认为2025年将是其NLRP3抑制剂管线的重要转折点，预计将公布VTX2735和VTX3232的关键临床数据，目标是在NLRP3炎症小体领域确立领先地位 [2] - 公司计划通过VTX2735和VTX3232的临床试验数据，探索在多种系统性和神经系统疾病中的治疗机会，包括那些已经验证IL-1拮抗作用为治疗方法的疾病 [2] 炎症性肠病（IBD）管线 - Tamuzimod（VTX002）在溃疡性结肠炎中的2期长期扩展（LTE）数据显示其具有潜在的最佳疗效，尽管单药治疗可能已达到疗效上限，但联合治疗可能成为未来的治疗方向 [9] - VTX958在克罗恩病中的2期试验未达到主要终点，但在内镜反应和炎症生物标志物方面显示出显著效果，公司正在分析52周的治疗数据以制定未来的开发策略 [9]

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company. On ...

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: •Event: Stifel 2024 Healthcare Conference Location: New York, NY Date: Monday, November 18, 2024 Time: 4:10-4:40 PM ET  •Even ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ | --- | --- | |-----------------------------------------------------------------------------------------------|-------------------------- ...

Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson's disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results ...

Shares of Ventyx Biosciences (VTYX) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi (SNY) . Per the terms of the deal, Sanofi will buy 70,601 of Ventyx's Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock. The proceeds from this investment are anticipated to enhance Ventyx's cash reserves. With t ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease. "We are excited to initiate this trial of VTX3232 in patients with early Parkinson's disease," said Mark Forman ...

SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and ...